Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Molecular Pharmaceutics ; 06:06, 2022.
Article in English | MEDLINE | ID: covidwho-2016525

ABSTRACT

Tracking the pathogen of coronavirus disease 2019 (COVID-19) in live subjects may help estimate the spatiotemporal distribution of SARS-CoV-2 infection in vivo. This study developed a positron emission tomography (PET) tracer of the S2 subunit of spike (S) protein for imaging SARS-CoV-2. A pan-coronavirus inhibitor, EK1 peptide, was synthesized and radiolabeled with copper-64 after being conjugated with 1,4,7-triazacyclononane-1,4,7-triyl-triacetic acid (NOTA). The in vitro stability tests indicated that [64Cu]Cu-NOTA-EK1 was stable up to 24 h both in saline and in human serum. The binding assay showed that [64Cu]Cu-NOTA-EK1 has a nanomolar affinity (Ki = 3.94 +/- 0.51 nM) with the S-protein of SARS-CoV-2. The cell uptake evaluation used HEK293T/S+ and HEK293T/S- cell lines that showed that the tracer has a high affinity with the S-protein on the cellular level. For the in vivo study, we tested [64Cu]Cu-NOTA-EK1 in HEK293T/S+ cell xenograft-bearing mice (n = 3) and pseudovirus of SARS-CoV-2-infected HEK293T/ACE2 cell bearing mice (n = 3). The best radioactive xenograft-to-muscle ratio (X/Nxenograft 8.04 +/- 0.99, X/Npseudovirus 6.47 +/- 0.71) was most evident 4 h postinjection. Finally, PET imaging in the surrogate mouse model of beta-coronavirus, mouse hepatic virus-A59 infection in C57BL/6 J mice showed significantly enhanced accumulation in the liver than in the uninfected mice (1.626 +/- 0.136 vs 0.871 +/- 0.086 %ID/g, n = 3, P < 0.05) at 4 h postinjection. In conclusion, our experimental results demonstrate that [64Cu]Cu-NOTA-EK1 is a potential molecular imaging probe for tracking SARS-CoV-2 in extrapulmonary infections in living subjects.

2.
Innovation in Aging ; 5:187-188, 2021.
Article in English | Web of Science | ID: covidwho-2011660
3.
Plasma Processes & Polymers ; : 1, 2022.
Article in English | Academic Search Complete | ID: covidwho-1990532

ABSTRACT

A little more than two decades after the introduction of the first microcavity plasma devices, a growing body of commercial products based on the remarkable properties of these low‐temperature, atmospheric plasmas is now available. Following a brief review of early microplasma lamp development, this article describes microplasma‐based devices and systems currently being manufactured for applications in photolithography, photopatterning, and other nanofabrication processes, such as atomic layer deposition, spectroscopic identification and analysis of materials (including wide bandgap crystals), the disinfection of drinking water in off‐grid communities, deactivating COVID‐19 and other pathogens in air and on surfaces in public spaces, and vacuum ultraviolet lamps for driving atomic clocks. The microplasma‐based treatment of otitis media in the human ear will also be discussed. [ FROM AUTHOR] Copyright of Plasma Processes & Polymers is the property of John Wiley & Sons, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

4.
Eur Rev Med Pharmacol Sci ; 26(10): 3760-3770, 2022 05.
Article in English | MEDLINE | ID: covidwho-1876425

ABSTRACT

OBJECTIVE: This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use. MATERIALS AND METHODS: We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). RESULTS: Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19. CONCLUSIONS: AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.


Subject(s)
Antirheumatic Agents , Autoimmune Diseases , COVID-19 , Rheumatic Diseases , Antirheumatic Agents/therapeutic use , COVID-19/drug therapy , Humans , Incidence , Rheumatic Diseases/drug therapy , Rheumatic Diseases/epidemiology
5.
Journal of Allergy and Clinical Immunology ; 149(2):AB141-AB141, 2022.
Article in English | Web of Science | ID: covidwho-1798221
6.
Influenza Other Respir Viruses ; 16(4): 680-689, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1764954

ABSTRACT

BACKGROUND: We sought to assess whether persistent COVID-19 symptoms beyond 6 months (Long-COVID) among patients with mild COVID-19 is associated with poorer health status, quality of life, and psychological distress. METHODS: This was a multicenter prospective cohort study that included adult outpatients with acute COVID-19 from eight sites during 2-week sampling periods from April 1 and July 28, 2020. Participants were contacted 6-11 months after their first positive SARS-CoV-2 to complete a survey, which collected information on the severity of eight COVID-19 symptoms using a 4-point scale ranging from 0 (not present) to 3 (severe) at 1 month before COVID-19 (pre-illness) and at follow-up; the difference for each was calculated as an attributable persistent symptom severity score. A total attributable persistent COVID-19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long-term follow-up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ-5D-5L), and psychological distress (Patient Health Questionnaire-4). The association between the total attributable persistent COVID-19 burden score and each outcome was analyzed using multivariable proportional odds regression. RESULTS: Of the 2092 outpatients with COVID-19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID-19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59-0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28-1.54) after adjusting for age, race, ethnicity, education, and income. CONCLUSIONS: In participants with mild acute COVID-19, the burden of persistent symptoms was significantly associated with poorer long-term health status, poorer quality of life, and psychological distress.


Subject(s)
COVID-19 , Psychological Distress , Adult , COVID-19/complications , COVID-19/epidemiology , Health Status , Humans , Prospective Studies , Quality of Life/psychology , SARS-CoV-2
7.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315413

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) has rapidly spread to more than 200 countries. Thus far, reports regarding multi-center data from throughout gestation in women with COVID-19 and newborn outcomes are scarce. Methods: : We retrospectively reviewed data from 92 pregnant women with COVID-19 (PW-COVID-19) and their 78 newborns from 27 hospitals in 12 regions of Hubei, China. The demographic, epidemiological, clinical, laboratory, and therapeutic data and pregnancy, perinatal, and neonatal outcomes were analyzed. Follow-up was censored until April 7, 2020. Findings: Median maternal age was 31.0 years (IQR 28·0-33·0), with nine patients in the first trimester, five in the second trimester, and 78 in the third trimester. None of the patients died, and most (92·4%) recovered and were discharged. Seventy-five deliveries (including three sets of twins) comprised 66 cesarean sections and nine vaginal deliveries, with 21 preterm and 57 full-term infants. Seventeen live births had radiological findings of pulmonary infection. One newborn tested positive for SARS-CoV-2 nucleic acid, and three newborns were viral antibody-positive: two IgG (+) and IgM (-), and one IgG (+) and IgM (+). The median suspected duration of virus exposure was 7 days (IQR 0 to 27). Interpretation: Compared to the pregnant women with other viral infections, such as SARS, MERS, and Zika virus infection, PW-COVID-19 had similar manifestations and relatively better outcomes. The termination time and delivery mode in PW-COVID-19 should be evaluated based on both the maternal and fetal situations. The possibility of maternal-to-fetal transmission of SARS-CoV-2 requires further investigation.Authors Shujie Liao and Renjie Wang contributed equally to this work.

8.
Sci Rep ; 12(1): 696, 2022 01 13.
Article in English | MEDLINE | ID: covidwho-1621270

ABSTRACT

Despite encouraging preclinical data, therapies to reduce ARDS mortality remains a globally unmet need, including during the COVID-19 pandemic. We previously identified extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a novel damage-associated molecular pattern protein (DAMP) via TLR4 ligation which regulates inflammatory cascade activation. eNAMPT is tightly linked to human ARDS by biomarker and genotyping studies in ARDS subjects. We now hypothesize that an eNAMPT-neutralizing mAb will significantly reduce the severity of ARDS lung inflammatory lung injury in diverse preclinical rat and porcine models. Sprague Dawley rats received eNAMPT mAb intravenously following exposure to intratracheal lipopolysaccharide (LPS) or to a traumatic blast (125 kPa) but prior to initiation of ventilator-induced lung injury (VILI) (4 h). Yucatan minipigs received intravenous eNAMPT mAb 2 h after initiation of septic shock and VILI (12 h). Each rat/porcine ARDS/VILI model was strongly associated with evidence of severe inflammatory lung injury with NFkB pathway activation and marked dysregulation of the Akt/mTORC2 signaling pathway. eNAMPT neutralization dramatically reduced inflammatory indices and the severity of lung injury in each rat/porcine ARDS/VILI model (~ 50% reduction) including reduction in serum lactate, and plasma levels of eNAMPT, IL-6, TNFα and Ang-2. The eNAMPT mAb further rectified NFkB pathway activation and preserved the Akt/mTORC2 signaling pathway. These results strongly support targeting the eNAMPT/TLR4 inflammatory pathway as a potential ARDS strategy to reduce inflammatory lung injury and ARDS mortality.


Subject(s)
Acute Chest Syndrome/metabolism , Mechanistic Target of Rapamycin Complex 2/metabolism , NF-kappa B/metabolism , Nicotinamide Phosphoribosyltransferase/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/physiology , Animals , Antibodies, Neutralizing/metabolism , Biomarkers/metabolism , COVID-19/metabolism , Disease Models, Animal , Inflammation/metabolism , Lipopolysaccharides/metabolism , Lung/metabolism , Male , Rats , Rats, Sprague-Dawley , SARS-CoV-2/pathogenicity , Swine
9.
Chinese General Practice ; 24(34):4349-4355, 2021.
Article in Chinese | Scopus | ID: covidwho-1600044

ABSTRACT

Background: In the context of public health emergencies, for example, the COVID-19 pandemic, community hospitals may face challenges to provide diagnosis and treatment services and to reduce the disease burden for patients with mental problems. However, general practitioners(GPs)' capabilities in diagnosing and treating mental disorders are unsatisfactory. Objective: To develop a system for identifying community-dwelling outpatients with mental disorders needing emergency management amid a public health emergency by GPs, to promote GPs' capabilities in diagnosing and treating mental disorders, and the health of such patients. Methods: From May to June 2020, based on a literature review and an investigation of work requirements for GPs, we formed a framework for identifying community-dwelling outpatients with mental disorders needing emergency management amid a public health emergency by GPs with indicators initially determined. Then we screened and revised the indicators according to the results of a two-round Delphi survey with 15 experts(in the field of general practice or mental health medicine), and finally determined the indicators(with a mean value of weighted importance>3.5, coefficient of variation <25%, and rate of getting full marks >20%) for the formal system identifying community-dwelling outpatients with mental disorders needing emergency management amid a public health emergency by GPs. Results: Information of the experts surveyed: 13 of them had a graduate degree, and 10 had a senior professional title. Positive coefficients of the experts: All the experts(100%) actively responded to the two rounds of survey. Authority coefficients of the experts: the authority coefficient of the six domains were >0.70. The degree of agreement between the experts: the Kendall's W in the second round of survey was 0.278(χ2=100.197, P<0.001), which was higher than 0.245(χ2=73.597, P<0.001)in the first round of survey. The final indicators: 24 indicators in six domains involving mental symptoms, diagnosis of mental illness, severity of mental illness, personality, physical status, family and social background. Conclusion: Our system may help GPs to high-efficiently identify community-dwelling outpatients with severe mental disorders needing emergency treatment or referrals. However, the accuracy of the system needs to be verified further. Copyright © 2021 by the Chinese General Practice.

10.
11.
Annals of Allergy, Asthma & Immunology ; 127(5):S51-S51, 2021.
Article in English | PMC | ID: covidwho-1509559
12.
Early Child Educ J ; 49(6): 1141-1154, 2021.
Article in English | MEDLINE | ID: covidwho-1491261

ABSTRACT

This study of South Korea's response to COVID-19 has three purposes. First, it uses document analysis to examine policies, strategies, and resources offered by the South Korean government and public organizations to support young children and families during the first 6 months of the pandemic. Next, it uses open-ended surveys with 30 directors of early childhood institutions to explore institutional-level supports and needs during the pandemic. Finally, it looks at the discrepancies between stated policies outlining the South Korea's response to COVID-19 and the lived experiences of early childhood educators as a route to arriving at recommendations for education policymakers and other stakeholders. To that end, we reviewed government documents (n = 84) containing early childhood education-related responses to Covid-19 established by the Ministry of Education, the Ministry of Health and Welfare, and other relevant government sectors. An online survey with 17 kindergarten and 13 child care center directors was also analyzed. Using content analysis, the findings revealed that the government's policies and guidance for Early Childhood Education and Care (ECEC) as well as the institutional supports for children and families were overall comprehensive in its scope. The analysis, based on the five tenets of the Whole Child approach, also indicated that the government's policy responses and services for ECEC focused mainly on the 'Safe' and 'Supported' tenets, while 'Challenged' was given the least amount of consideration. The survey responses demonstrated different measures taken by kindergartens and child care centers highlighting the separate nature of 'education' and 'care' in South Korea, while also indicating limited resources for supporting children's psychological well-being and for children and families in need. This overview provides a foundation for further discussion and research on the impact of Covid-19 on ECEC in South Korea and beyond.

13.
Sleep Health ; 7(6): 666-674, 2021 12.
Article in English | MEDLINE | ID: covidwho-1487972

ABSTRACT

OBJECTIVE: Sleep may be especially important for maintaining health and well-being in daily life amid the stress of the coronavirus disease 2019 (COVID-19) pandemic. This preregistered study examined the associations of sleep quality, duration, and efficiency with next-day physical symptoms, affect, and stressors during the COVID-19 pandemic in North America, in addition to evaluating individual differences in COVID-19 threat as a moderator. METHOD: From mid-March to early August 2020, 1025 adults from Canada and the United States aged 18-91 reported COVID-19 threat at baseline and subsequently completed twice-daily diaries for one week about their sleep, negative affect, stressors, and physical symptoms. RESULTS: Within-persons, nights with better-than-usual sleep quality predicted lower next-day negative affect, physical symptoms, and stressor occurrence. Better-than-usual sleep efficiency and longer-than-usual sleep duration also predicted lower next-day physical symptoms. COVID-19 threat ratings moderated several of these associations, such that individuals with higher COVID-19 threat showed weaker within-person associations of sleep duration and efficiency with next-day well-being, compared to individuals with lower-to-moderate levels of COVID-19 threat. For the reversed direction of association, stressor occurrence predicted shorter-than-usual sleep that night, but no other links between daily well-being and subsequent sleep were observed. DISCUSSION: Sleep quality, efficiency, and duration were important predictors of daily health and well-being during the COVID-19 pandemic, but the protective associations between sleep and next-day well-being were attenuated among people with higher COVID-19 threat. These findings highlight the role of heightened stress contexts when considering the benefits of sleep on daily health and well-being.


Subject(s)
COVID-19 , Adult , Humans , North America/epidemiology , Pandemics , SARS-CoV-2 , Sleep , United States/epidemiology
14.
Annals of Allergy, Asthma & Immunology ; 127(5):S51-S51, 2021.
Article in English | CINAHL | ID: covidwho-1460589
15.
Public Health ; 201: 48-54, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1458680

ABSTRACT

OBJECTIVES: The aim of the study was to evaluate whether unemployment and underemployment are associated with mental distress and whether employment insecurity and its mental health consequences are disproportionately concentrated among specific social groups in the United States during the COVID-19 pandemic. STUDY DESIGN: This is a population-based longitudinal study. METHODS: Data came from the Understanding America Study, a population-based panel in the United States. Between April and May 2020, 3548 adults who were not out of the labor force were surveyed. Analyses using targeted maximum likelihood estimation examined the association of employment insecurity with depression, assessed using the 2-item Patient Health Questionnaire, and anxiety, measured with the 2-item Generalized Anxiety Disorder scale. Stratified models were evaluated to examine whether employment insecurity and its mental health consequences are disproportionately concentrated among specific social groups. RESULTS: Being unemployed or underemployed was associated with increased odds of having depression (adjusted odds ratio [AOR] = 1.66, 95% confidence interval [CI] = 1.36-2.02) and anxiety (AOR = 1.50, 95% CI = 1.26, 1.79), relative to having a full-time job. Employment insecurity was disproportionately concentrated among Hispanics (54.3%), Blacks (60.6%), women (55.9%), young adults (aged 18-29 years; 57.0%), and those without a college degree (62.7%). Furthermore, Hispanic workers, subsequent to employment insecurity, experienced worse effects on depression (AOR = 2.08, 95% CI = 1.28, 3.40) and anxiety (AOR = 1.95, 95% CI = 1.24, 3.09). Those who completed high school or less reported worse depression subsequent to employment insecurity (AOR = 2.44, 95% CI = 1.55, 3.85). CONCLUSIONS: Both unemployment and underemployment threaten mental health during the pandemic, and the mental health repercussions are not felt equally across the population. Employment insecurity during the pandemic should be considered an important public health concern that may exacerbate pre-existing mental health disparities during and after the pandemic.


Subject(s)
COVID-19 , Pandemics , Depression/epidemiology , Employment , Female , Humans , Longitudinal Studies , Mental Health , SARS-CoV-2 , Unemployment , United States/epidemiology , Young Adult
16.
Chinese Journal of Evidence-Based Medicine ; 21(6):676-682, 2021.
Article in Chinese | Scopus | ID: covidwho-1449170

ABSTRACT

Objective To systematically review the safety of different types of COVID-19 vaccines in the population. Methods Web of Science, PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and CBM databases were electronically searched to collect randomized controlled trials (RCTs) which reported safety of COVID-19 vaccines in population. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed by using RevMan 5.4 software. Results A total of 5 RCTs involving 2 431 subjects were included. The results of the meta-analysis showed that COVID-19 vaccines developed more fever symptoms than placebo (RR=2.21, 95%CI 1.38 to 3.54, P=0.000 9). However, there was no significant difference in the incidence of adverse reactions (RR=1.28, 95%CI 0.96 to 1.70, P=0.10), injection site adverse reactions (RR=1.47, 95%CI 0.65 to 3.36, P=0.36) and systemic adverse reactions (RR=0.96, 95%CI 0.78 to 1.17, P=0.66) between two groups. Conclusions Current evidence shows that COVID-19 vaccines are sufficiently safe. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions. © 2021 West China University of Medical Science. All rights reserved.

17.
Nano Biomedicine and Engineering ; 13(3):225-228, 2021.
Article in English | EMBASE | ID: covidwho-1403981

ABSTRACT

The novel coronavirus pneumonia, a global pandemic disease named as coronavirus disease 2019, has caused enormous losses on the health and economies of people all over the world, while there is still a lack of quick and sensitive diagnostic method and effective therapy. Developing rapid diagnostic method for coronavirus disease 2019 has become exceptional urgent. Herein we report a rapid diagnostic method for the novel coronavirus through monitoring the volatile biomarkers in human exhaled breath. The breath volatile biomarkers are derived from the metabolism of novel coronavirus, including acetoin, 2,4,6-trimethylpyridine, 3-methyl tridecane, tetradecane, isooctyl alcohol, pentadecane, hexadecane, 1-methylene-1H-indene. By comparing the types and concentrations of the volatile biomarkers in human exhaled breath combined with SERS sensor, we could distinguish between the healthy person and the patients with coronavirus disease 2019. This work confirms that various volatile organic compounds metabolized by novel coronavirus can be employed for rapidly screening of patients with coronavirus disease 2019, and has broad application prospects in the prevention and control of the epidemic.

18.
Journal of Nuclear Medicine ; 62(SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1312299

ABSTRACT

Objectives: Prior studies have documented multiple organ injuries related to COVID-19. These findings raisedconcerns on the impact of injuries on the health of patients discharged. We aim to identify and evaluate the minimalresidual lesions as well as the critical organs by applying the 18F-FDG PET/CT dynamic modeling approach fordischarged COVID-19 patients. Methods: Seven healthy volunteers (without COVID-19 infection or tumor history) completed static 18F-FDGPET/CT scan as control group 1. Dynamic 18F-FDG PET scans were performed for 19 patients including 7discharged COVID-19 patients (COVID-19 group) and 12 non-metastatic, newly diagnosed thyroid cancer (controlgroup 2). Dynamic 18F-FDG PET/CT scans were carried out two to three months after discharge for COVID-19group. Dynamic scans were performed from the apex of lung to the lower margin of liver. Patlak graphic analysis (Ki calculation) based on the dynamic modeling and SUV analysis from conventional static data were performed. Inaddition, COVID-19 group also completed lung function test one month after discharge. Results: COVID-19 patients were consecutively recruited, consisting of four severe and three mild pneumoniacases. Figure 1A shows the time course of recovery for a representative COVID-19 patient. One patient suffered anincreased 18F-FDG uptake of the lower lobe of bilateral lungs and a slightly impaired lung function. Although nosignificant differences were found for SUV between COVD-19 group and control group 1 in myocardial ( p =0.1677) and liver ( p = 0.0701), the SUV of lungs, brain, spleen, kidney, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, and pelvisacrum in the COVID-19 group were significantly higher than that in the control group 1( p < 0.05 for all;Figure 1B ). Consistent with static results, the Ki values of myocardial and liver were notsignificantly different between COVID-19 group and control group 2. However, the Ki values of lung from severepneumonia were significantly higher than that of mild pneumonia ( p = 0.0034) and control group 2 ( p = 0.0003;Figure 1C ). Conclusion: Given such small number of enrolled, this preliminary study suggested that 18F-FDGPET/CT provided a reliable estimate of residual lesions and may act as a potential tool for evaluating recoverystatus in discharged COVID-19 subjects.

19.
2021 International Conference on Management of Data, SIGMOD 2021 ; : 2614-2627, 2021.
Article in English | Scopus | ID: covidwho-1299241

ABSTRACT

Recently, there has been a pressing need to manage high-dimensional vector data in data science and AI applications. This trend is fueled by the proliferation of unstructured data and machine learning (ML), where ML models usually transform unstructured data into feature vectors for data analytics, e.g., product recommendation. Existing systems and algorithms for managing vector data have two limitations: (1) They incur serious performance issue when handling large-scale and dynamic vector data;and (2) They provide limited functionalities that cannot meet the requirements of versatile applications. This paper presents Milvus, a purpose-built data management system to efficiently manage large-scale vector data. Milvus supports easy-to-use application interfaces (including SDKs and RESTful APIs);optimizes for the heterogeneous computing platform with modern CPUs and GPUs;enables advanced query processing beyond simple vector similarity search;handles dynamic data for fast updates while ensuring efficient query processing;and distributes data across multiple nodes to achieve scalability and availability. We first describe the design and implementation of Milvus. Then we demonstrate the real-world use cases supported by Milvus. In particular, we build a series of 10 applications (e.g., image/video search, chemical structure analysis, COVID-19 dataset search, personalized recommendation, biological multi-factor authentication, intelligent question answering) on top of Milvus. Finally, we experimentally evaluate Milvus with a wide range of systems including two open source systems (Vearch and Microsoft SPTAG) and three commercial systems. Experiments show that Milvus is up to two orders of magnitude faster than the competitors while providing more functionalities. Now Milvus is deployed by hundreds of organizations worldwide and it is also recognized as an incubation-stage project of the LF AI & Data Foundation. Milvus is open-sourced at https://github.com/milvus-io/milvus. © 2021 Owner/Author.

20.
International Journal of Dermatology and Venereology ; : 68-69, 2021.
Article in English | Scopus | ID: covidwho-1281895

ABSTRACT

The coronavirus disease 2019 (COVID-19) outbreak affects the use of biologics for psoriatic patients, in the way that the consequential immunosuppression potentially alters a patient's susceptibility to the virus or deteriorate the condition if the patient is infected or even change the prognosis of infection. Therefore, authors reviewed currently available recommendations from international psoriasis academic organizations and specialists, and summarized them with the specific situation in China. We are trying to provide guidance to the use of biologics for psoriatic patients in the following contexts: patients on biologic therapy, patients being considered for biologic therapy initiation, patients with low-risk or high-risk of SARS-CoV-2 coronavirus infection, patients tested negative or positive for the nucleic acid testing of virus. © 2021 Lippincott Williams and Wilkins. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL